INDV vs MRNA: fair value comparison
Indivior Pharmaceuticals, Inc. and Moderna, Inc. · Updated 2026-10-19
MRNA has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, INDV currently ranks higher by quality score.
| INDV | MRNA | |
|---|---|---|
| Verdict | Undervalued | No estimate yet |
| Last price | $32.45 | $218.01 |
| 12-month range | $24.78–$41.83 | $22.36–$236.50 |
| Rank by discount to fair value | #17 of 108 Healthcare | — |
| Rank by quality score | #195 of 301 Healthcare | #197 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Stable | Contracting |
| Revenue growth | Modest | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | — |
| 52-week position | The lower-middle quarter | The top quarter |
Full single-stock breakdowns: INDV fair value analysis · MRNA fair value analysis